Heme oxygenase-1 (HO-1) exerts vaso-protective effects. Such benefit in diabetic vasculopathy however remains unclear. We hypothesize that bilirubin mediates HO-1-induced vascular benefits in diabetes. Diabetic db/db mice were treated with hemin (HO-1 inducer) for two weeks, and aortas were isolated for functional and molecular assays. Nitric oxide (NO) production was measured in cultured endothelial cells. Hemin treatment augmented endothelium-dependent relaxations (EDRs) and elevated Akt and eNOS phosphorylation in db/db mouse aortas, which were reversed by HO-1 inhibitor SnMP or HO-1 silencing virus. Hemin treatment increased serum bilirubin and ex vivo bilirubin treatment improved relaxations in diabetic mouse aortas, which was reversed by Akt inhibitor. Biliverdin reductase silencing virus attenuated the effect of hemin. Chronic bilirubin treatment improved EDRs in db/db mouse aortas. High glucose-induced reductions in Akt and eNOS phosphorylation, and NO production were reversed by hemin and bilirubin. The effect of hemin but not bilirubin was inhibited by biliverdin reductase shRNA. Furthermore, bilirubin augmented EDRs in renal arteries from diabetic patients. In summary, HO-1-induced restoration of endothelial function in diabetic mice is most likely mediated by bilirubin which preserves NO bioavailability through the Akt/eNOS/NO cascade, suggesting bilirubin as a potential therapeutic target for clinical intervention of diabetic vasculopathy.
Cardiovascular disease (CVD) is the leading cause of death and disability for patients with diabetes (1) . Hyperglycemia and insulin resistance reduce NO bioavailability and diminish the anti-atherogenic capacity of the endothelium, resulting in platelet aggregation, increased vascular contractility, and accelerated atherosclerosis. Thus, strategies aim at preserving endothelial function may help alleviate diabetic vasculopathy (2) .
Heme oxygenase (HO) catalyzes heme to form carbon monoxide (CO), Fe 2+ and biliverdin; the latter is converted into unconjugated bilirubin by biliverdin reductase (BVR) (3) . Two distinct isoforms of HO have been identified: heme oxygenase 1 (HO-1) and heme oxygenase 2 (HO-2).
While HO-2 is constitutively expressed, the expression of HO-1 is normally low but inducible.
HO-1 can be up-regulated by stimuli such as lipopolysaccharide and H 2 O 2 in various cells or organs (4; 5) . Limited studies show an altered HO-1 expression under metabolic conditions. HO-1 expression and activity is increased in human umbilical vein endothelial cells (HUVECs) when exposed to 10 mM glucose for 48 hours compared to 5.5 mM glucose, but remains unchanged when exposed to 20 mM glucose for 48 hours (6) . HO-1 mRNA is down-regulated in skeletal muscle of diabetic patients, but it is increased in liver and visceral fat of obese patients (7; 8) , suggesting that HO-1 expression can be differently regulated in major metabolic organs under different disease states. Growing evidence suggests HO-1 as a potential target for intervention of diabetes. Induction of HO-1 in obese mice increases plasma adiponectin and improves insulin sensitivity; while it decreases visceral and abdominal adiposity and plasma pro-inflammatory cytokines (9) . HO-1 over-expression reduces lymphocytic infiltration in Langerhans islets and retards the progression of type 1 diabetes (10) . HO-1 also protects against high glucose-induced impairment of endothelial-dependent relaxations (EDRs) in rat aortas (11) and high glucose-induced endothelial cell apoptosis (6; 12) . These studies indicate that HO-1 induction may serve as a potential therapeutic strategy to treat diabetic vascular complications. However, the precise intracellular mechanisms mediating the vaso-protective benefits of HO-1 remain largely unexplored.
Bilirubin is converted from biliverdin by BVR. Clinical studies show an inverse association between serum bilirubin concentration with incidences of myocardial infarction, peripheral artery disease, and stroke (13) (14) (15) (16) and serum bilirubin level is lower in diabetic patients (17) . Of note,
Gilbert syndrome patients, that with higher serum unconjugated bilirubin, are less prone to major adverse cardiovascular events (18) and individuals with higher serum bilirubin are better protected from developing metabolic disorders in a 4-year retrospective longitudinal study (19) . Bilirubin is a potent antioxidant and efforts have been directed to determine whether bilirubin can be used to treat diseases associated with oxidative stress. Indeed, atazanavir, a drug that raises unconjugated bilirubin levels, enhances the plasma antioxidant capacity and improves EDRs in diabetic patients (20) .
This study examined the hypothesis that unconjugated bilirubin mediates vascular benefits of HO-1 induction to restore the impaired endothelial function in diabetic db/db mice and investigated the possible mechanisms involved. The present new findings support the clinical observation that bilirubin is vaso-protective in diabetes.
Vessel preparation
After mice were sacrificed, thoracic aortas were removed, placed in ice- (21) . The baseline tension was set at 3 mN and all rings were equilibrated for 60 min was before the start of the experiments.
Functional study
Aortic rings were contracted by 1 µmol/L phenylephrine to induce a sustained tension before acetylcholine (ACh, 10 -8 to 10 -5 mol/L) was added cumulatively to trigger endothelium-dependent relaxations. Endothelium-independent relaxations induced by NO donor sodium nitroprusside (SNP, 10 -8 to 10 -5 mol/L) were compared in arteries from different groups.
Organ culture of aortic rings
Mouse aortas were cultured for 24-h at 37°C in Dulbeco's Modified Eagle's Medium (DMEM, Gibco, Gaithersberg, MD, USA) supplemented with 10% FBS (Gibco) and 100 IU/ml penicillin plus 100 µg/ml streptomycin as described ( 
Measurement of nitrite in mouse aortas
Mouse aortas were treated with hemin (5 µmol/L) or bilirubin (1 µmol/L) for 24 h, followed by addition of 10 µmol /L acetylcholine (10 min) to stimulate NO generation with the presence of nitrate reductase to reduce nitrate to nitrite. Aortas were then homogenized and nitrite level in the supernatants was measured by a Griess reagent kit (Molecular Probes, Eugene, OR, USA) and normalized by the protein content.
Construction of HO-1 shRNA adeno-associated virus
Short hairpin (sh)RNA sequence targeting mouse HO-1 was obtained from sigma 
Knockdown of biliverdin reductase by adenoviral shRNA transduction
The U6 promoter and 1.9kb stuffer sequence were excised from pLKO.1 (addgene) with NotI/ XhoI and cloned into pShuttle. shRNA targeting mouse BLVRA (sigma, TRCN0000042128) was generated similarly to the pLKO.1 system (26). Briefly, the forward (CCGGGCCAAATGTAGGA GTCAATAACTCGAGTTATTGACTCCTACATTTGGCTTTTTG) and reverse (TCGAGAAAAA GCCAAATGTAGGAGTCAATAACTCGAGTTATTGACTCCTACATTTGGC) oligos were annealed and ligated to pShuttle-U6 predigested with AgeI and XhoI. The pAd-U6-shBLVRA plasmid was produced as reported previously (27) and linearized by PacI and transfected to Hek-293 cell to produce the viral particle.
Overexpression of HO-1 by adenoviral transduction
db/db mice were injected with HO-1 overexpressing adenovirus (10 9 pfu, a gift from Jun Yu, Prince of Wales Hospital in Hong Kong) through tail vein and kept for 4 days before sacrificed.
Knockdown of Akt in HUVECs
HUVECs were purchased from Lonza (San Diego, CA) and cultured in Endothelial Cell Growth Medium (EGM, Lonza) supplemented with 10 % FBS plus 1 % penicillin/streptomycin. HUVECs were transfected with a dominant negative Akt construct (DN-Akt) by electroporation using Nucleofector II machine (Amaxa/Lonza, Walkersville, MD, USA) according to the manufacturer's instruction.
Measurement of NO and ROS generation in HUVECs
NO production in HUVECs was measured by Olympus Fluoview FV1000 laser scanning confocal system using 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF- and measured using Fluoview FV1000 confocal system at excitation 488 nm and emission 520 nm.
To detect NO mediated antioxidant capacity of bilirubin, NO scavenger oxidized-hemoglobin (20 µmol/L) was used together with bilirubin in HG-treated HUVECs. HUVECs were incubated with 5 µmol/L dihydroethidium (DHE, Invitrogen) for 30 min and fluorescence intensity was measured using Fluoview FV1000 confocal system at excitation 515 nm and emission 585 nm.
Western blotting
Protein lysates from mouse aortas or HUVECs were separated by electrophoresis and then transferred onto an immobilon-P polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA, USA 
Immunohistochemical staining of biliverdin reductase
Human renal arteries were frozen in OCT compound (Sakura Finetek, CA, U.S.A), cut into 10 µm-sections on a microtome (Leica Microsystems, Germany) and fixed with 4% paraformaldehyde. 
Statistical Analysis
Results are means±SEM of n experiments. The relaxation was expressed as percentage reduction in phenylephrine-induced contraction. Concentration-response curves were constructed using GraphPad Prism software (Version 4.0, San Diego, CA, USA). Statistical significance was determined by two-tailed Student's t-test or one-way ANOVA followed by Bonferroni post-hoc tests when more than two treatments were compared. p<0.05 indicates statistical significance.
RESULTS

HO-1 induction restored EDRs in diabetic mice
Acetylcholine ( EDRs and HO-1 expression (Fig. 1E&F ). In addition, we also used DIO mice to confirm the findings in db/db mice. Hemin administration for two weeks augmented EDRs and HO-1 expression in DIO mouse aortas (Supplemental Fig. 3A&B ), suggesting HO-1 is most likely to mediate hemin-induced improvement of EDRs in diabetic mice.
PI3K/Akt/eNOS contributed to vascular benefits of HO-1 induction in diabetic mice
The phosphorylation levels of Akt (The308) and eNOS (Ser1177) in aortas were lower in db/db mice than db/m + mice. In vivo hemin treatment restored the diminished phosphorylation of Akt and eNOS and such effects were reversed by co-treatment with SnMP ( 
Bilirubin improved EDRs in db/db mouse aortas
The concentration of serum unconjugated bilirubin was 77.5 ± 7.8 nmol/L in db/db and 350.0 ± 3.9 nmol/L in db/m + mice. Hemin treatment increased bilirubin to 201.4 ± 13.6 nmol/L, which was inhibited by SnMP (Fig. 3A) . (Fig. 3C ) but not that of bilirubin (Fig. 3D ) was reversed by BVR shRNA. Successful inhibition of BVR expression by shRNA adenovirus was shown by Western blotting (Fig. 3E ) and immunohistochemical staining (Fig. 3F) . To confirm the role of bilirubin to mediate the vascular benefit of HO-1 in vivo, we treated db/db mice with bilirubin for 2 weeks. Chronic bilirubin administration improved EDRs in db/db mouse aortas (Fig. 4A ) accompanied with increased phosphorylation of Akt (Thr308) and eNOS (Ser1177) (Fig. 4B-D) . These results further indicate that bilirubin is most likely to mediate the effect of HO-1 induction to improve endothelial function.
Hemin and unconjugated bilirubin restored NO production in HUVECs
High glucose (HG, 36-h) reduced Ca 2+ ionophore A23187 (100 nmol/L)-stimulated NO elevation detected by DAF-DA in HUVECs, compared with normal glucose (Fig. 5A&B) . Hemin or bilirubin restored the HG-impaired NO production (Fig. 5A, B&C) . Ex vivo treatment with hemin and bilirubin also raised nitrite level (which reflects tissue NO level) in db/db mouse aortas (Supplemental Fig. 4 ). Akt inhibitor V (5 µmol/L) abolished the effect of hemin and bilirubin while SnMP only inhibited the effect of hemin on NO production (Fig. 5B&C) . Inhibition of Akt activity by Ad-DN-Akt, the plasmid expressing dominant negative Akt abolished the effect of both hemin and bilirubin (Fig. 5D ). In addition, treatment with hemin or bilirubin increased phosphorylation of Akt and eNOS in HG-treated HUVECs. Again, the effect of hemin was abolished by SnMP while the effect of hemin and bilirubin was reversed by Akt inhibitor V (Fig. 5E-H ).
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Down-regulation of biliverdin reductase diminished the effect of hemin in HUVECs
GFP shRNA adenovirus served as the control virus. Hemin increased bilirubin level in medium culturing HUVECs, which was diminished by BVR shRNA adenovirus (Supplemental Fig. 5A ).
The stimulatory effect of hemin on Akt and eNOS phosphorylation in high glucose-treated
HUVECs was reversed by BVR shRNA adenovirus (Fig. 6A-C) . Likewise, hemin-stimulated NO production in HUVECs was inhibited by BVR shRNA adenovirus (Supplemental Fig. 5B&C ). By contrast, the effect of bilirubin remained unchanged by BVR shRNA ( 
Bilirubin improved EDRs in renal arteries from diabetic patients.
The HbA1c concentrations in diabetic patients are presented in Supplemental Table 1 . Compared to renal arteries form patients without cardio-metabolic complications (control), EDRs in renal arteries from diabetic patients (DM) were impaired, which were augmented after 24-h exposure to bilirubin
(1 µmol/L) (Fig. 7A&B) . BVR expression was detected in the endothelium in human renal arteries by immunohistochemistry (Fig. 7C ).
DISCUSSION
Although HO-1 is known to benefit vascular function, whether such beneficial effects were directly or indirectly induced by HO-1 induction remains poorly understood. HO-1 degrades heme to form biliverdin, CO, and Fe
2+
; the former is further converted into unconjugated bilirubin. Bilirubin is increasingly recognized to be vaso-protective in cardio-metabolic diseases (18; 20) and total plasma bilirubin concentration is lower in diabetic patients (17) . The present study also shows a reduced serum level of unconjugated bilirubin in db/db mice, which is increased following two-week hemin treatment. Importantly, ex vivo treatment with unconjugated bilirubin (at 1 µM, a concentration comparable to that detected in the serum of non-diabetic mice) and two-week administration of bilirubin (i.p.) to db/db mice resulted in similar vascular benefits as hemin to restore EDRs. More definitely, silencing BVR using shRNA adenovirus reverses ex vivo hemin-induced improvement of EDRs in db/db mouse aortas and hemin-stimulated NO production in HUVECs. By contrast, the beneficial effects of bilirubin were unaffected by BVR shRNA. Taken together, bilirubin is the most likely mediator of the vaso-protective action of HO-1 induction. Likewise, bilirubin is also reported to mediate the anti-atherogenic action of HO-1 through inhibiting vascular inflammation (28).
The present study provides the first piece of evidence showing that ex vivo treatment with bilirubin improves EDRs in renal arteries from diabetic patients, further suggesting that bilirubin is vaso-protective in human. It should be noted that the diabetic patients were with renal carcinoma and had different duration of diabetes and HbA1c levels (Supplemental Table 1 It is worthwhile to note that HO-1 induction in vivo moderately reduces fasting glucose and insulin levels in db/db mice and also improved insulin sensitivity (Supplemental Fig. 8 ). Previous studies showed that HO-1 induction improves insulin sensitivity and reduces adiposity, which is associated with increased adiponectin release (9; 40). Thus, the metabolic benefit is likely to contribute albeit to a lesser degree to the restoration of endothelial function in hemin-treated diabetic mice through HO-1 up-regulation in adipose tissues (40; 41). Although the role of vascular HO-1 induction in improved insulin sensitivity cannot be ruled out, increased expression of insulin receptor substrate 1 (IRS1) and Akt phosphorylation resulting from HO-1 over-expression in liver, adipose tissue, and skeletal muscle might play a greater role in hemin-induced increase in systematic insulin sensitivity (Supplemental Fig. 9 ). It is therefore probable that improved insulin YH is the guarantor of this study. In vivo hemin treatment improved endothelial function in diet-induced obese mice.
Compared to lean mice, ACh-induced endothelium-dependent relaxations were impaired in diet-induced obese (DIO) mice (Supplemental Fig. 3A ), which were reversed by two-week hemin treatment. Hemin treatment also increased HO-1 expression, phosphorylation of Akt (Thr308) and eNOS (Ser1177) in mouse aortas (Supplemental Fig. 3B , C&D). 
BVR shRNA adenovirus transduction inhibited the effect of hemin in HUVECs
Hemin treatment (5 µmol/L, 36-h) of HUVECs increased the bilirubin level in culture medium, which was reversed by transduction with BVR shRNA adenovirus (Supplemental Fig. 5A ). In addition, hemin restored NO production that was impaired by high glucose (HG, 30 mmol/L, 36 h) in HUVECs. This effect of hemin was reversed after transduction of BVR shRNA adenovirus. However, the effect of bilirubin to restore NO production was not affected by BVR shRNA adenovirus transduction (Supplemental Fig. 5B&C ). Hemin slightly increased insulin sensitivity in db/db mice. Chronic hemin treatment did not change body weight and lipid profile in db/db mice (Supplemental Table 2 ). But fasting blood glucose and plasma insulin level was decreased. Oral glucose tolerance test and intraperitoneal insulin tolerance test showed an improved glucose tolerance and insulin sensitivity (Supplemental Fig. 8 ).
Supplemental Figure 8 . Hemin increased insulin receptor substrate 1 (IRS1) expression, Akt phosphorylation and HO-1 expression in liver, adipose tissue and skeletal muscle of db/db mice. Chronic hemin treatment increased IRS1 expression and Akt phosphorylation, as well as HO-1 expression in the liver, epididymal fat and skeletal muscle of db/db mice, which may account for the improved systematic insulin sensitivity (Supplemental Fig. 9 ). 
Additional Discussion
Akt is one of eNOS activators in endothelial cells. Reduced Akt phosphorylation is reported in arteries of diabetic animals or in high glucose-treated endothelial cells while Akt activation augments endothelium-dependent relaxations in aortas of diabetic mice (1) . Previous studies showed that high glucose exposure suppresses Akt phosphorylation probably through increasing oxidative stress and protein kinase C activation (2-5). The present study shows a decreased Akt phosphorylation in db/db mouse aortas. Serum bilirubin concentration is reported to be lower in diabetic patients than in healthy subjects (6) . We also detected less serum bilirubin level in diabetic mice, indicating that lower serum bilirubin may partly account for the reduced aortic Akt phosphorylation in diabetic mice. In view of the serum antioxidant capacity of bilirubin (7), oxidative stress in association with reduced bilirubin is probably another factor involved in decreased Akt phosphorylation under diabetic conditions (2) (3) (4) (5) . Our in vitro experiments show that high glucose exposure stimulates ROS generation and reduces Akt phosphorylation in human endothelial cells without changing the levels of HO-1 and bilirubin. In vitro and in vivo results show a different impact of hyperglycemia on bilirubin levels in cultured endothelial cells and in serum of diabetic mice probably due to far more complex mechanisms regulating circulating bilirubin concentration which is likely controlled by the balance between production and excretion of bilirubin in vivo. Although the present study does not provide direct data to support the possibility that decreased serum bilirubin is associated with decreased Akt phosphorylation in db/db mouse aortas, increased bilirubin production by hemin treatment and bilirubin administration to db/db mice can effectively increase Akt phosphorylation. The present study shows that bilirubin activates Akt/eNOS/NO cascade to lower oxidative stress as the major mechanism to restore the impaired endothelial function in hemin-treated diabetic mice.
